Terumo Medical Corporation, a wholly-owned subsidiary of Terumo Corporation, announced the US launch of its SurTract™ Safety Syringe, powered by SafeR® passive safety technology developed by Roncadelle Operations S.r.l. The SurTract Syringe will be distributed across hospitals, clinics, and emergency-care settings beginning in the first quarter of 2026.

SafeR technology provides the SurTract Syringe with a fully passive, automatic retraction mechanism that withdraws the needle into the plunger immediately after use – helping reduce the risk of needle-stick injuries for physicians, and providing patients with a smooth and comfortable injection due to less plunger pressure. The syringe system also preserves standard clinical technique while offering enhanced safety, reliability and ease of use.

Other benefits include:
• A customizable needle selection designed for use exclusively with SurTract Syringes, allowing physicians the opportunity to create the combination they need for optimal patient care.
• A blunt needle, preventing dullness and allowing a change of needle for drawing up aspiration.
• Less medical waste due to a lack of an external plastic safety sheath.
• Reduction in medication waste due to the low dead space syringe*.

“The SurTract Syringe combines Terumo’s trusted clinical know-how with Roncadelle’s validated SafeR technology to deliver a simple, effective solution for safer injections,” said Bob Klock, Vice President, Terumo Medical Corporation. “It gives healthcare providers more – and better – treatment options for their patients, which is our ultimate goal.”

“Terumo has significantly advanced injection safety with the integration of our SafeR technology,” said Dr. Fred Metzmann, Chief Business Development Officer at Roncadelle Operations. “Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals.”